INTRODUCTION
Mastalgia is one of the commonest presenting complains in breast clinics with prevalence rate of 30%. 1 It's usually classified in cyclical mastalgia (75%) and non-cyclical mastalgia 25%.
2
Cyclical mastalgia is defined as cyclical swelling, discomfort and pain in one or both breasts occurring mostly one week before menstruation and settling with its onset. Although no single underlying mechanism has been mentioned in literature; various hypothesis regarding its pathophysiology have been put forth; including increased serum prolactin levels, hypersensitivity to estrogen, decreased serum progesterone, deficiency of antioxidants or gamma linoleic acid levels in body. Although not associated with an increase in risk of malignancy, cyclical mastalgia is often severe enough to effect marital relationships in 41% 3 and sleep pattern in 35% of its victims, Ten percent of patients suffer for nearly half of their lives. 13 One of these supplements, Vitamin E or alpha tocopherol, acts as an antioxidant agent having stabilizing effect on breast cells' epithelium protecting them from injurious free radicals that are produced in sundry metabolic processes of body.
14 Due to its low side effect profile, Vitamin E has long been promoted as a safe treatment option especially in fertile women suffering from cyclical mastalgia. 15 Evening primrose oil (Oenothera biennis) is plant oil rich in omega 6 fatty acids, especially gamma linolenic acid (GLA). Patients of cyclical mastalgia are often postulated to have lower ratio of GLA to unsaturated fatty acids causing breast tissue epithelium to become hypersensitive to circulatory hormones levels. Another hypothesis suggests significant role of GLA at genetic levels in lipoxygenase and cyclooxygenase pathways producing antiinflammatory eicosanoids.
Over the time, both supplements have made their mark as acceptable options in treating cyclical mastalgia. However, the supremacy of one over other is disputed. Due to lack of evidence-based guidelines, most of the surgeons lean on their intuition or personal preference in choosing one drug over other. The rationale of current study is to generate local data in this aspect so that recommendations can be given for better patient management.
Study Design
After approval from hospital's ethical committee, a randomized controlled single blinded trial was conducted at Surgical Unit-1 of Holy Family Hospital Rawalpindi, for a period of six months i.e. June to Dec 2016 (permitted by the Research and Ethical Committee, Rawalpindi Medical College and Allied Hospitals, RMC/PR_01/Jan 2015). A sample size of 380 patients, 190 in each group, was calculated using WHO calculator. Moderate cyclical mastalgia was defined as pain and heaviness in breasts beginning before menstruation and relieving at end of it with pain score between 4-7 on visual analogue scale. All females of reproductive age (15-45 years) were included. Those who were pregnant, lactating or had a history of breast trauma were excluded. All patients were clearly informed about the purpose, procedure and blinding process of the study. After obtaining written informed consent, group allocation was done by simple lottery method. A total of 380 chits with half labelled as A and remaining half labelled as B were put in a box. Every patient drew a chit and was allocated to the corresponding group. Patient remained unaware of their group type throughout the study. Group A received Vitamin E capsules 400 mg once daily whereas group B received evening primrose oil 500 mg capsules twice daily. Visual analogue scale was used to calculate pain scores at beginning and and end of study period. Data were entered and analyzed using the Statistical Package for Social Sciences (SPSS), version 23.0 (IBM Corp., Armonk, NY).
For the quantitative variables of the study i.e. age, duration of disease and visual analogue scores, means along with standard deviations were calculated.
Effect modifiers like age and duration of disease were controlled by stratification. Post stratification independent sample t-test was applied. A p-value < 0.05 was considered statistically significant.
RESULTS
Total 380 patients were enrolled in each group. Study was conducted for a period of 6 months. Mean age of patients was calculated to be 29.35±6.76 years. Those enrolled in Vitamin E group had mean age of 31.013±6.83 years and those in evening primrose oil had 27.70±6.36 years. All details regarding age are given in Table-I. Pretreatment and post treatment mean pain scores were calculated in both groups. Difference in pain scores after treatment for six months were also calculated. There was significant difference of pain scores between two groups. Difference was found to be higher in vitamin E group than evening primrose oil group. Details are given in Table- calculated. In vitamin E group mean duration of symptoms was 4.85+2.04 months while in evening primrose oil group mean duration was 4.82 2.37 months. All details are given in Table-III. Stratification for age and duration of symptoms were done and are summarized in Table- Both are a part of guidelines given by multiple centers, worldwide. However little work has been done in comparing their efficacy against each other. This study showed cyclical mastalgia to be predominantly a problem of young women less than 30 years of age (61.05%). Most of the patients had been suffering for quite some time (4.83±2.205 months) before presenting to breast clinic. Patients having pain scores between 4 to 7 were included in the study. Those with score 8 or more were considered to be suffering from severe mastalgia. They received additional drugs like oral and topical NSAIDs and tamoxifen etc. and were not included in the study. Six months later, a change in pain scores in both groups was noted (Vitamin E =2.05±1.89, EPO=0.76±1.5). This was significant only for Vitamin E receiving group (p value < 0.05). drawn conflicting conclusions. In 2010, Pruthi et al, in a pilot study, compared effects of both supplements when used alone or in combination for treatment of cyclical mastalgia. It was a pilot study with small sample size and high dropout rate. No drug was found to be superior, but a general trend of benefit was noted in all treatment arms. 15 In 2011, Alvandipour et al, from Iran, also showed that both supplements were equally effective. 16 However, Fathizadeh et al, endorsed that although both drugs reduced pain, EPO was in fact better than Vitamin E when given in daily doses of 3 gram for several months (p value p < 0.001). 17 This result is in contradiction to our findings and is may be due to smaller dosage of EPO (1 gm per oral daily) used in our study.
This was interesting as several studies in past have
Stratification of the data was done for both age and duration of symptoms. Two age groups of 15-30 years and 31-45 years were made. In Vitamin E group, younger patients showed better improvement (2.12±1.84) than older ones (1.97±1.94). EPO group also showed similar findings but there the difference in change in score was not very great. This special effectiveness of Vitamin E for ages less than 30 is important because majority sufferers also belonged to a younger group (61.05%); thus, making it a choice medication for almost 2/3 rd of the patient population.
Stratification was also done for duration of symptoms, which revealed that those presenting early i.e. within 6 months of symptom had greater changes in mean pain sores than those presenting late.
Compliance was an issue found during the study. Most patients found it cumbersome to adhere to regimens lasting six months. Moreover, relief with both supplements was slow in onset. This caused few patients (n=21) to opt for other treatment options e.g. NSAIDs, tamoxifen, bromocriptine. These offered swifter relief albeit at cost of side effects. Such patients were considered drop outs and not included in study. Editing.
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